One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis.
BMC Pulm Med
; 22(1): 101, 2022 Mar 24.
Article
in English
| MEDLINE | ID: covidwho-1759734
ABSTRACT
BACKGROUND:
In Germany, the first case of coronavirus disease 2019 (COVID-19) was registered on 28 January 2020. By February 2021, the third wave of the pandemic began. So far, only few data are available on the SARS-CoV-2 prevalence and the clinical impact of an infection in patients with cystic fibrosis (CF).METHODS:
From February 2020 until March 2021, we screened 156 CF patients for anti-SARS-CoV-2 IgG antibodies (serology) and the presence of SARS-CoV-2 in deep throat saliva or nasopharyngeal swabs (molecular testing). From patients with confirmed SARS-CoV-2 infection, we recorded symptoms and collected clinical data.RESULTS:
In total, 13 patients (8.3%) were tested positive for SARS-CoV-2 infection, most of them during the second and the beginning third wave of the pandemic. Ten positive tested patients described symptoms linked to COVID-19. The most common symptom was cough followed by fatigue and headache. SARS-CoV-2 infection did not impair lung function. No positive tested patient needed to be hospitalized.CONCLUSIONS:
SARS-CoV-2 infections in patients with CF are not as rare as initially anticipated, as frequent testing revealed. However, infected patients did not experience more severe clinical courses or worse clinical outcome. Our observation is in line with published reports indicating that individuals with CF are not at higher risk for severe COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cystic Fibrosis
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
English
Journal:
BMC Pulm Med
Year:
2022
Document Type:
Article
Affiliation country:
S12890-022-01900-8
Similar
MEDLINE
...
LILACS
LIS